Abstract
Metachromatic leukodystrophy (MLD) is a rare inborn error of metabolism leading to severe neurological symptoms and early death. Hematopoietic SCT (HSCT) is considered a treatment option, but results are inconsistent and comparison with natural history is practically missing. We compare a girl with juvenile MLD 10 years after allogeneic HSCT not only with her untreated sister, but also with a large cohort of untreated patients. The girl received HSCT at the age of 5 years when first motor signs appeared. Over 10 years she was stable with respect to her clinical course and gained cognitive abilities. Magnetic resonance imaging (MRI) showed clear regression of white matter changes and magnetic resonance spectroscopy (MRS) demonstrated a reversal of the initial choline increase and N-acetyl-aspartate (NAA) decrease. Only axonal demyelinating neuropathy showed some progression. Her gross motor function and MRI-scores were clearly better compared with her sister and the cohort of untreated patients. Difference to her sister became apparent only 4 years after HSCT. We conclude that HSCT, early in the course of disease, can lead to stabilization of juvenile MLD with a course clearly different from the natural history. HSCT may prevent disease progression, if performed sufficient time before loss of walking, which typically initiates rapid deterioration.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Heim P, Claussen M, Hoffmann B, Conzelmann E, Gaertner J, Harzer K et al. Leukodystrophy incidence in Germany. Am J Med Genet 1997; 71: 475–478.
Poorthuis BJ, Wevers RA, Kleijer WJ, Groeber JE, de Jong JG, van Weely S et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999; 105: 151–156.
von Figura K, Gieselmann V, Jacken J . Metachromatic leukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease, 8th edn. McGraw-Hill: New York, 2001, pp 3695–3724.
Moser H, Lees M . Sulfatide lipidosis: metachromatic leukodystrophy. In: Stanbury JB, Wyngaarden JB, Fredrickson DS (eds) The Metabolic Basis of Inherited Disease. McGraw-Hill: New York, 1965, pp 539–559.
Kehrer C, Blumenstock G, Gieselmann V, Krägeloh-Mann I . The natural course of gross motor deterioration in Metachromatic Leukodystrophy. Dev Med Child Neurol 2011; 53: 850–855.
Kehrer C, Kustermann-Kuhn B, Raabe C, Krägeloh-Mann I . Natural history of metachromatic leukodystrophy (MLD) - clinical course. Eur J Pediatr 2008; 167: 374.
Kumperscak HG, Plesnicar BK, Zalar B, Gradisnik P, Seruga T, Paschke E . Adult metachromatic leukodystrophy: a new mutation in the schizophrenia-like phenotype with early neurological signs. Psychiatr Genet 2007; 17: 85–91.
Groeschel S, Kehrer C, Engel C, Dali C, Bley A, Steinfeld R et al. Metachromatic Leukodystrophy: natural course of cerebral MRI changes in relation to clinical course. J Inherit Metab Dis 2011; 34: 1095–1102.
Kruse B, Hanefeld F, Christen HJ, Bruhn H, Michaelis T, Hanicke W et al. Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol 1993; 241: 68–74.
Sener RN . Metachromatic leukodystrophy. Diffusion MR imaging and proton MR spectroscopy. Acta Radiol 2003; 44: 440–443.
i Dali C, Hanson LG, Barton NW, Fogh J, Nair N, Lund AM . Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy. Neurology 2010; 75: 1896–1903.
Krivit W . Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin Immunopathol 2004; 26: 119–132.
Krivit W, Peters C, Shapiro EG . Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 1999; 12: 167–176.
Peters C, Steward CG . Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003; 31: 229–239.
Biffi A, Lucchini G, Rovelli A, Sessa M . Metachromatic leukodystrophy: an overview of current and prospective treatments. Bone Marrow Transplant 2008; 42 (Suppl 2): S2–S6.
Polten A, Fluharty AL, Fluharty CB, Kappler J, von Figura K, Gieselmann V . Molecular basis of different forms of metachromatic leukodystrophy. N Engl J Med 1991; 324: 18–22.
Kehrer C, Blumenstock G, Raabe C, Krageloh-Mann I . Development and reliability of a classification system for gross motor function in children with metachromatic leucodystrophy. Dev Med Child Neurol 2011; 53: 156–160.
Tewes U, Rossmann P, Schallberger U . HAWIK-III. Hamburg-Wechsler-Intelligenztest für Kinder. 3rd edn. Verlag Hans Huber: Bern, 1999.
Melchers P, Preuß U . K-ABC: Kaufman assessment battery for children. Deutschsprachige Fassung. Durchführungs- und Auswertungshandbuch. 2nd edn. Swets & Zeitlinger: Amsterdam, 1994.
Eichler F, Grodd W, Grant E, Sessa M, Bizzi A, Bley A et al. Metachromatic leukodystrophy: a scoring system for brain MR observations. AJNR 2009; 30: 1893–1897.
Clas P, Groeschel S, Wilke M . A semi-automatic algorithm for determining the demyelination load in metachromatic leukodystrophy. Acad Radiol 2012; 19: 26–34.
Kidd D, Nelson J, Jones F, Dusoir H, Wallace I, McKinstry S et al. Long-term stabilization after bone marrow transplantation in juvenile metachromatic leukodystrophy. Arch Neurol 1998; 55: 98–99.
Clarke JT, Skomorowski MA, Chang PL . Marked clinical difference between two sibs affected with juvenile metachromatic leukodystrophy. Am J Med Genet 1989; 33: 10–13.
Arbour LT, Silver K, Hechtman P, Treacy EP, Coulter-Mackie MB . Variable onset of metachromatic leukodystrophy in a Vietnamese family. Pediatr Neurol 2000; 23: 173–176.
Cable C, Finkel RS, Lehky TJ, Biassou NM, Wiggs EA, Bunin N et al. Unrelated umbilical cord blood transplant for juvenile metachromatic leukodystrophy: a 5-year follow-up in three affected siblings. Mol Genet Metab 2011; 102: 207–209.
Pierson TM, Bonnemann CG, Finkel RS, Bunin N, Tennekoon GI . Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy. Ann Neurol 2008; 64: 583–587.
Ding XQ, Bley A, Kohlschutter A, Fiehler J, Lanfermann H . Long-term neuroimaging follow-up on an asymptomatic juvenile metachromatic leukodystrophy patient after hematopoietic stem cell transplantation: Evidence of myelin recovery and ongoing brain maturation. Am J Med Genet 2011; 158A: 257–260.
Görg M, Wilck W, Granitzny B, Suerken A, Lukacs Z, Ding X et al. Stabilization of juvenile metachromatic leukodystrophy after bone marrow transplantation: a 13-year follow-up. J Child Neurol 2007; 22: 1139–1142.
Kapaun P, Dittmann RW, Granitzny B, Eickhoff W, Wulbrand H, Neumaier-Probst E et al. Slow progression of juvenile metachromatic leukodystrophy 6 years after bone marrow transplantation. J. Child Neurol 1999; 14: 222–228.
Acknowledgements
Samuel Groeschel received institutional research support from the German Federal Ministry of Education and Research, the European Commission (LeukoTreat) and from Shire plc. Christiane Kehrer received institutional research support from the German Federal Ministry of Education and Research. The natural-history study was supported by a grant of the German Federal Ministry of Education and Research (BMBF) funding the German LEUKONET (01 GM 0835).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Ingeborg Krägeloh-Mann was member of the scientific board of the Scandinavian biopharmaceutical company ZYMENEX for a world-wide clinical trial I-study for enzyme replacement with the ZYMENEX’s product ‘Metazym’ in 2007. This did not imply any involvement, nor funding in the present study. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Krägeloh-Mann, I., Groeschel, S., Kehrer, C. et al. Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort. Bone Marrow Transplant 48, 369–375 (2013). https://doi.org/10.1038/bmt.2012.155
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.155
Keywords
This article is cited by
-
Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi)
Orphanet Journal of Rare Diseases (2022)
-
T2-Pseudonormalization and Microstructural Characterization in Advanced Stages of Late-infantile Metachromatic Leukodystrophy
Clinical Neuroradiology (2021)
-
Early clinical course after hematopoietic stem cell transplantation in children with juvenile metachromatic leukodystrophy
Molecular and Cellular Pediatrics (2020)
-
Psychiatric Symptoms Associated with Inborn Errors of Metabolism
SN Comprehensive Clinical Medicine (2020)
-
Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective
Orphanet Journal of Rare Diseases (2019)